Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal
Pfizer Prices $31bn Debt Offering To Fund Seagen Buy
Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy.
